Atenolol is a commonly prescribed drug in the beta-blocker class. It is primarily used to treat hypertension (high blood pressure) and angina pectoris (chest pain due to reduced blood flow to the heart). Known for its effectiveness and relatively mild side effect profile, atenolol has been an integral part of cardiovascular medicine since its introduction. In this blog, we are going to explore different aspects of atenolol, R & D, global market size, market drivers, API manufacturing, etc.
Let's explore the different aspects of atenolol:-
Atenolol's journey from its initial discovery to its widespread use today involved extensive research and clinical trials. Developed in the 1970s, the drug was intended to selectively block beta-adrenergic receptors in the heart and blood vessels, leading to a reduction in heart rate and blood pressure. Research is continuing to examine its effectiveness in treating other conditions beyond its primary indication.
Atenolol drug development involves a rigorous process to ensure safety, efficacy, and compliance with regulatory standards. From the synthesis of active pharmaceutical ingredients (APIs) to formulation into tablets and capsules, pharmaceutical companies adhere to Good Manufacturing Practices (GMP) to produce high-quality medicines. Development also involves clinical trials to determine the therapeutic benefits and safety profile of the drug.
The global market size of atenolol is expected to grow at a compound annual growth rate of approximately 5% from 2023 to 2035. The market is expected to reach USD 28 billion by the end of 2035, up from approximately USD 11 billion in 2022. (Courtesy of Globe News Wire)
Key players in the atenolol market include Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Bio-Rad Laboratories, Inc., Sysmex Corporation, Zydus Pharmaceuticals Inc., Ipca Laboratories Limited, and Siemens Healthineers AG.
Several manufacturers across the globe are involved in the production of atenolol active pharmaceutical ingredients (API). India is a leading country in API manufacturing. Companies such as Alembic Pharmaceuticals, Aurobindo Pharma, and Cadila Healthcare manufacture Atenolol API.
- Other countries such as China, Japan, and South Korea have also made significant contributions.
Chemxpert database provides insights into pharmaceutical manufacturing and provides data on customers, suppliers, market size, clinical trials, regulatory insights, and pricing mechanisms of atenolol. This valuable resource helps you make decisions, forecast market trends, and understand the competitive landscape.
In summary, atenolol plays a vital role in cardiovascular health and its market growth reflects the increasing need for effective treatment. Researchers and manufacturers continue to explore sustainable ways to improve its production and effectiveness.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!